UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

The Medication Adherence Program

Not Applicable

Conditions: Treatment
Diabetes

Interventions: Other: Medication Adherence Program (MAP)

First Posted Date: 2009-02-06

Last Posted Date: 2009-09-30

Lead Sponsor: University of Washington

Target Recruit Count: 240

Registration Number: NCT00838344

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Phase 2

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm

Interventions: Drug: Bendamustine Hydrochloride
Other: Quality-of-Life Assessment

First Posted Date: 2009-01-16

Last Posted Date: 2017-07-07

Lead Sponsor: University of Washington

Target Recruit Count: 45

Registration Number: NCT00823797

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Phase 2

Completed

Conditions: Skin Metastases
Recurrent Breast Cancer
Male Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: imiquimod
Drug: Abraxane
Other: laboratory biomarker analysis
Genetic: RNA analysis
Other: immunoenzyme technique

First Posted Date: 2009-01-14

Last Posted Date: 2018-01-02

Lead Sponsor: University of Washington

Target Recruit Count: 15

Registration Number: NCT00821964

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Immunomodulation Following Transfusion

Phase 4

Completed

Conditions: Blood Component Transfusion

Interventions: Biological: Standard blood components
Biological: Leukoreduced blood components
Biological: Leukoreduced and irradiated

First Posted Date: 2008-12-18

Last Posted Date: 2017-12-26

Lead Sponsor: University of Washington

Target Recruit Count: 287

Registration Number: NCT00810810

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Northwest Hospital, Seattle, Washington, United States

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

Not Applicable

Completed

Conditions: Major Depressive Disorder
Drug Abuse
Bipolar Disorder
Schizophrenia

Interventions: Behavioral: Contingency Management
Behavioral: Non Contingent Control Condition

First Posted Date: 2008-12-17

Last Posted Date: 2016-11-08

Lead Sponsor: University of Washington

Target Recruit Count: 176

Registration Number: NCT00809770

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women

Not Applicable

Completed

Conditions: Genital Herpes

Interventions: Drug: matching placebo
Drug: acyclovir

First Posted Date: 2008-12-15

Last Posted Date: 2013-12-11

Lead Sponsor: University of Washington

Target Recruit Count: 88

Registration Number: NCT00808405

Locations: 🇿🇦
Reproductive Health and HIV Research Unit (RHRU), Johannesburg, South Africa
🇿🇲
Center for Infectious Disease Research of Zambia (CIDRZ), Lusaka, Zambia

Prediction of Post-Cesarean Section Pain

Conditions: Postoperative Pain

Interventions: Other: Psychophysical testing, questionnaires, and genetics

First Posted Date: 2008-11-27

Last Posted Date: 2011-09-26

Lead Sponsor: University of Washington

Target Recruit Count: 800

Registration Number: NCT00799162

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇧🇷
Hospital e Maternidade Santa Joana, São Paulo, Brazil
🇺🇸
University of Washington, Seattle, Washington, United States

and more 2 locations

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Phase 1

Completed

Conditions: HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: HER-2/neu peptide vaccine
Procedure: leukapheresis
Biological: ex vivo-expanded HER2-specific T cells
Drug: cyclophosphamide
Biological: sargramostim
Other: laboratory biomarker analysis

First Posted Date: 2008-11-14

Last Posted Date: 2017-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 23

Registration Number: NCT00791037

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Phase 2

Terminated

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: sunitinib malate
Drug: capecitabine

First Posted Date: 2008-11-10

Last Posted Date: 2017-06-01

Lead Sponsor: University of Washington

Target Recruit Count: 41

Registration Number: NCT00787787

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Paraesophageal Hernia Repair With Small Intestine Submucosa

Conditions: Hiatal Hernia
Paraesophageal Hernia

First Posted Date: 2008-11-05

Last Posted Date: 2009-10-01

Lead Sponsor: University of Washington

Target Recruit Count: 108

Registration Number: NCT00786084

Locations: 🇺🇸
Washington University School of Medicine, St Louis, Missouri, United States
🇺🇸
The Oregon Clinic, PC, Portland, Oregon, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy